NEONasdaq

NeoGenomics Inc.

Healthcare·Oncology·Commercial·Fort Myers, FL, United States
Oncology

NeoGenomics Inc. (NEO): 1 pipeline candidate · ~79 mo cash runway. Updated within the last hour.

7.3/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway10.0

79.0 months

Financial Health9.1

D/E 0.62 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider Signal4.3

0 buys · 1 sell (180d)

A transparent, data-derived signal for NeoGenomics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$1.4B

Cash

$146.1M

Quarterly Burn

$8.1M

Runway

79.0 mo

Revenue

$186.7M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jan 2033
Today~87 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
radarApproved

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

254

Total value held

$955.6M

HolderSharesValue
blackrock, inc.19,957,502$148.1M
vanguard capital management llc11,311,646$83.9M
greenhouse funds lllp9,215,903$68.4M
vanguard portfolio management llc7,622,187$56.6M
first trust advisors lp6,162,371$45.7M
braidwell lp5,617,402$41.7M
state street corp5,119,838$38.0M
d. e. shaw & co., inc.4,164,183$30.9M
schroder investment management group3,568,578$25.7M
nomura asset management international inc.3,452,587$25.6M

Showing top 10 of 254 institutional holders of NeoGenomics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Anthony P. Zook

Frequently asked questions

How many drug candidates are in NeoGenomics Inc.'s pipeline?

NeoGenomics Inc. (NEO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is NeoGenomics Inc.'s lead drug candidate?

NeoGenomics Inc.'s most advanced tracked candidate is radar (Approved) for solid tumor malignancies.

What is NeoGenomics Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, NeoGenomics Inc. has approximately 79.0 months of cash runway.

What is NeoGenomics Inc.'s market capitalization?

NeoGenomics Inc.'s market capitalization is approximately $1.4B.

Who is the CEO of NeoGenomics Inc.?

Mr. Anthony P. Zook is the chief executive officer of NeoGenomics Inc. (NEO).

Get the full picture on NeoGenomics Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.